Cresilon announced its revolutionary hemostatic gel TRAUMAGEL(R) has received an Innovative Technology contract from Vizient(R) the nation's largest provider-driven healthcare performance improvement ...
A team of researchers from Texas A&M University is using clay as a possible solution for extending the critical time frame — often referred to as the golden hour — before severe blood loss from an ...
A novel hemostatic sealant based on the in situ gel formation of gelatin catalyzed by thrombin and crosslinked by transglutaminase was designed. The aim of this study was to investigate the efficacy ...
Although there is no clinical evidence of a role for the hemostatic system in the progression of atherosclerosis, ample experimental data indicate that platelets and the coagulation system are ...
NEW ORLEANS, LA—Recombinant factor VIIa slowed hematoma growth in patients with a spontaneous intracerebral hemorrhage (ICH) when administered within 2 hours of onset, but treatment significantly ...
NEW ORLEANS -- There is still hope that recombinant factor VIIa (rFVIIa) may be a good hemostatic treatment for acute intracerebral hemorrhage (ICH) under the right circumstances -- just not the way ...
Non-compressible hemorrhage control is a challenging topic both on the battlefields and in civilian life. Blooming in the non-compressible hemostatic materials development emerged in recent years and ...
Baltimore, MD (3/22/2023) — BC3 Technologies, a privately held medical device company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SEAL Hemostatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results